GIM-122 / Georgiamune - LARVOL DELTA

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov) - P1/2 | N=111 | Recruiting | Sponsor: Georgiamune Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor • LAG3

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies (clinicaltrials.gov) - P1/2 | N=111 | Not yet recruiting | Sponsor: Georgiamune Inc

New P1/2 trial • Oncology • Solid Tumor • LAG3

Georgiamune Inc. Achieves US FDA Clearance for Investigational New Drug (IND) Application and Secures $75 Million in Series A Financing (PRNewswire) - "Today, Georgiamune Inc...announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for GIM-122, a dual-functioning monoclonal antibody. Furthermore, the company successfully completed a $75M Series A financing, positioning Georgiamune as a promising new biotechnology company in the fields of oncology and autoimmune diseases. The clearance of Georgiamune's first IND represents a significant milestone for the company as it embarks on its first clinical trial in oncology....Georgiamune plans to initiate its phase 1/2 clinical trial in the second half of 2023 and continue development of its extensive first-in-class pipeline for cancer and autoimmune diseases with high unmet needs."

Financing • IND • P1/2 data • Oncology • Solid Tumor